CSL Behring

CSL Behring products

A

• Andembry® — garadacimab

  • Indication: prophylaxis to prevent recurrent attacks of hereditary angioedema (HAE); first treatment targeting coagulation factor XIIa (approved U.S. June 2025).

B

• Berinert® — C1-esterase inhibitor

  • Indication: on-demand treatment of HAE attacks.

• Beriplex® P/N — prothrombin complex concentrate

  • Indication: urgent warfarin reversal during acute major bleeding.

• Beriate®, Helixate®, Humate‑P®, Monoclate P, Mononine® — coagulation factor VIII and IX products for hemophilia A and B management.

• Biostate, Fibrogammin® P, Corifact®, Cluvot® — treatment of factor XIII deficiency and fibrinogen deficiency.

• Privigen®, Hizentra®, Carimune®, Sandoglobulin®, Vivaglobin® — immunoglobulin (IgG) replacement therapies for primary immunodeficiency disorders.

• Zemaira® / Respreeza® — alpha‑1‑proteinase inhibitor for emphysema caused by Alpha‑1 Antitrypsin Deficiency.

H

• HAEGARDA® — C1-esterase inhibitor subcutaneous

  • Indication: prophylaxis for HAE.

• Hizentra® CIDP, Privigen® CIDP, Hizentra® PID, Privigen® PID — immunoglobulin therapies for chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PID).

K

• Kcentra® — prothrombin complex concentrate (4-factor)

  • Indication: reversal of anticoagulation effects (warfarin) in serious bleeding or before surgery.

• Hemgenix® — etranacogene dezaparvovec

• Indication: one-time gene therapy for hemophilia B; delivers functional Factor IX DNA via AAV vector.